BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 18021342)

  • 21. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.
    Wan Rosalina WR; Teh LK; Mohamad N; Nasir A; Yusoff R; Baba AA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):237-41. PubMed ID: 21545474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.
    Dervieux T; Blanco JG; Krynetski EY; Vanin EF; Roussel MF; Relling MV
    Cancer Res; 2001 Aug; 61(15):5810-6. PubMed ID: 11479220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
    Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
    Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    van Egmond R; Chin P; Zhang M; Sies CW; Barclay ML
    Aliment Pharmacol Ther; 2012 May; 35(10):1181-9. PubMed ID: 22486532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Not Available].
    Fakhoury M; Jacqz-Aigrain E; ; de Beaumais T; Médard Y
    Therapie; 2010; 65(3):187-93. PubMed ID: 27392985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Significance of TPMT activity and TGNs level detection for individualizing 6-mercaptopurine chemotherapy].
    Gu LJ; Ye QD; Liang AB; Zhao JC; Xue HL; Tang YN; Chen J; Ye YC
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):18-21. PubMed ID: 12679004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
    J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia.
    Donnan JR; Ungar WJ; Mathews M; Hancock-Howard RL; Rahman P
    Pediatr Blood Cancer; 2011 Aug; 57(2):231-9. PubMed ID: 21344614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interference free and simplyfied liquid chromatography-based determination of thiopurine S-methyltransferase activity in erythrocytes.
    Khalil MN; Erb N; Khalil PN; Escherich G; Janka-Schaub GE
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(1):105-11. PubMed ID: 15897017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment.
    Coulthard SA; Matheson EC; Hall AG; Hogarth LA
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1385-91. PubMed ID: 15571264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.
    Lennard L; Welch JC; Lilleyman JS
    Br J Clin Pharmacol; 1997 Nov; 44(5):455-61. PubMed ID: 9384462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.
    Lennard L; Cartwright CS; Wade R; Vora A
    Br J Haematol; 2015 Apr; 169(2):228-40. PubMed ID: 25441457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans.
    Loennechen T; Yates CR; Fessing MY; Relling MV; Krynetski EY; Evans WE
    Clin Pharmacol Ther; 1998 Jul; 64(1):46-51. PubMed ID: 9695718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic polymorphism of thiopurine S-methyltransferase in Argentina.
    Laróvere LE; de Kremer RD; Lambooy LH; De Abreu RA
    Ann Clin Biochem; 2003 Jul; 40(Pt 4):388-93. PubMed ID: 12880540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis.
    Heneghan MA; Allan ML; Bornstein JD; Muir AJ; Tendler DA
    J Hepatol; 2006 Oct; 45(4):584-91. PubMed ID: 16876902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
    Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MTHFR and TYMS genotypes influence TPMT activity and its differential modulation in males and females.
    Karas-Kuzelicki N; Milek M; Mlinaric-Rascan I
    Clin Biochem; 2010 Jan; 43(1-2):37-42. PubMed ID: 19748501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.